Enanta Pharmaceuticals (ENTA) Q1 2026 earnings summary

Executive summary

• Focused on developing small molecule drugs for virology and immunology, with wholly-owned programs in RSV, COVID-19, HBV, and type 2 inflammatory diseases.

• Advanced RSV portfolio with Phase 3 enabling activities for zelicapavir and positive Phase 2b data in high-risk adults, showing significant symptom resolution and reduced hospitalization.

• Expanded immunology pipeline with new MRGPRX2 inhibitor program and progress on KIT and STAT6 inhibitors, targeting chronic inflammatory diseases.

• Royalty revenue is primarily from AbbVie's MAVYRET/MAVIRET for HCV, with a royalty sale agreement in place with OMERS for a portion of future royalties.

• Cash, cash equivalents, and marketable securities totaled $241.9 million as of December 31, 2025, expected to fund operations into fiscal 2029.

Financial highlights

• Total revenue for the quarter ended December 31, 2025 was $18.6 million, up from $17.0 million year-over-year, driven by higher HCV sales and MAVYRET/MAVIRET royalties.

• Net loss for the quarter was $11.9 million ($0.42 per share), a significant improvement from a net loss of $22.3 million ($1.05 per share) in the prior year period.

• Research and development expenses decreased to $20.9 million from $27.7 million, mainly due to lower RSV clinical trial costs.

• General and administrative expenses fell to $9.0 million from $12.8 million, reflecting lower stock-based compensation and legal expenses.

• Cash, cash equivalents, and marketable securities totaled $241.9 million at quarter end.

Outlook and guidance

• Existing cash and expected royalty streams are projected to fund operations and capital expenditures into fiscal 2029.

• IND filings planned for EDP-978 in Q1 2026 and EPS-3903 in 2H 2026, with Phase 1 data for EDP-978 expected in Q4 2026.

• Development candidate selection for MRGPRX2 program targeted for 2H 2026.

• External R&D expenses are expected to decrease in the next 12 months as Phase 2 RSV studies conclude and business development opportunities are explored.